Results from the phase 1 trial of duvelisib among patients with TCL. (A) Plot of the best response and time on treatment in PTCL (left) and CTCL (right) patients. “Other” indicates ALCL (2 patients), EATL, and NK-TCL; LCT-MF, mycosis fungoides with large-cell transformation; SS, Sézary syndrome. (B) Pretreatment and posttreatment PET-CT imaging in a patient with PTCL and PR to duvelisib. (C) Serum factors measured at baseline and cycle 1 day 8 (C1D8) in patients treated with duvelisib and the change from baseline in cytokine levels were calculated and compared for the patient groups based on response. Error bars indicate standard deviation. *P < .05; **P < .01 by Mann-Whitney U test.